Scientists have discovered a new potential therapy that may reduce brain damage following stroke in type 2 diabetic patients. The suggested drug, linagliptin, is already approved for the treatment of type 2 diabetes under the brand names Tradjenta and Trajenta.
However, the scientists at Karolinska Institutet in Sweden hope that this new results, presented in the scientific journal Diabetes, also opens up the possibility to decrease brain injury after stroke in other patient groups with a high stroke risk.
Stroke is when part of the neural tissue in the brain is damaged due to lack of oxygen delivery, either caused by a blood clot (thrombosis) or rupture of a blood vessel. People suffering from diabetes are at higher risk to develop stroke than the average population. The only acute treatment to decrease the consequences (disability) of a stroke commonly available is thrombolysis, which dissolves the blood clot in the occluded vessels of the brain when quickly administered after onset of symptoms.
However, this therapy is only available for approximately 10 per cent of stroke patients and has potential severe side effects, mainly brain hemorrhage. Furthermore, the effect of thrombolysis treatment is reduced in diabetic patients as diabetes in itself causes a sensitive vessel structure.
The chemical substance at the basis of the current finding is called linagliptin, and is already commercialized as an antidiabetic drug under the trade name Tradjenta (US) and Trajenta (Worldwide). Combined with exercise and special diet, linagliptin lowers the levels of glucose in the blood in adults with type 2 diabetes.
In their study, the scientists administered linagliptin or placebo to diabetic mice, before and after having induced a stroke experimentally. By using this study design, the scientists simulated the situation of type 2 diabetic patients under the treatment of linagliptin.
The results show that linagliptin is able to stimulate neuroprotection and largely reduce the brain damage following stroke, independent of its glucose-lowering effects. This in turn suggests that type 2 diabetic patients, when treated with linagliptin, might have a better prognosis after a stroke than diabetics receiving other treatments.
The current study is the result of a collaborative effort between scientists at the Department of Clinical Science and Education, the Stockholm South General Hospital (Södersjukhuset), and the pharmaceutical company Boehringer Ingelheim Pharma GmbH & Co. The work was conceived and directed by Dr Cesare Patrone and Professor Åke Sjöholm, while Dr Vladimer Darsalia led the experiments of the study.
Publication: ‘The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride’, Vladimer Darsalia, Henrik Ortsäter, Anna Olverling, Emilia Darlöf, Petra Wolbert, Thomas Nyström, Thomas Klein, Åke Sjöholm, and Cesare Patrone, Diabetes, online 4 December 2012.
Source: Karolinska Institutet